Synthase Biotech is an early-stage company commercialising a novel enzyme technology that works to prevent and repair damage caused by the oxidation of lipids in cell membranes, a key process for damage and ageing within cells.
The Aloxsyn® enzyme has the potential to significantly extend the lifespan of cellular products. Currently, Aloxsyn® is being applied in the fertility space to improve artificial insemination (AI) and in vitro fertilisation (IVF) practices and outcomes in livestock as a beachhead market. This enzyme has broad potential applications, such as improving human fertility through to extending the shelf life of foods and beverages.
Synthase has secured critical partners in the Aotearoa New Zealand and US livestock genetics and fertility industries, allowing for trials of the Aloxsyn® enzyme for both IVF and AI. Recent large-scale trials in the US have demonstrated statistically significant positive results, paving the way for adoption by large customers. Synthase also owns 50% of Lipoxagen, a related drug development company. Matū works closely with Synthase to provide strong governance, capital raising expertise, and support their ongoing strategy and business development.